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Recently published diagnostic criteria for mild cognitive impairment with Lewy bodies (MCI-LB) 
include five neuropsychiatric supportive features (non-visual hallucinations, systematised delusions, 
apathy, anxiety and depression). We have previously demonstrated that the presence of two or 
more of these symptoms differentiates MCI-LB from MCI due to Alzheimer’s disease (MCI-AD) with a 
likelihood ratio >4.  The aim of this study was to replicate the findings in an independent cohort. 
 
Methods 
Participants ≥60 years old with MCI were recruited. Each participant had a detailed clinical, cognitive 
and imaging assessment including FP-CIT SPECT and cardiac MIBG. The presence of neuropsychiatric 
supportive symptoms was determined using the neuropsychiatric inventory (NPI). Participants were 
classified as MCI-AD, possible MCI-LB and probable MCI-LB based on current diagnostic criteria. 
Participants with possible MCI-LB were excluded from further analysis. 
 
Results 
Probable MCI-LB (n=28) had higher NPI total and distress scores than MCI-AD (n=30).  59% of MCI-LB 
had two or more neuropsychiatric supportive symptoms compared with 9% of MCI-AD (likelihood 
ratio 6.5, p<0.001). MCI-LB participants also had significantly greater delayed recall and a lower 





MCI-LB is associated with significantly greater neuropsychiatric symptoms than MCI-AD. The 
presence of two or more neuropsychiatric supportive symptoms as defined by MCI-LB diagnostic 
criteria is highly specific and moderately sensitive for a diagnosis of MCI-LB. The cognitive profile of 
MCI-LB differs from MCI-AD, with greater executive and lesser memory impairment, but these 







In recent years, diagnostic criteria have been developed for prodromal diagnosis of a range of 
neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD) (Albert 
et al., 2011, Litvan et al., 2012). Recently, research criteria for mild cognitive impairment with Lewy 
bodies (MCI-LB) have been developed (McKeith et al., 2020). The accurate identification of MCI-LB is 
important to allow research into this phase of the disease, to help patients and their families 
understand the symptoms they are experiencing and to facilitate the identification of treatable 
symptoms such as REM sleep behaviour disorder, parkinsonism and constipation. MCI-LB is 
differentiated from other causes of MCI on the basis of the presence of core clinical features 
associated with dementia with Lewy bodies (DLB) (cognitive fluctuations, recurrent visual 
hallucinations, REM sleep behaviour disorder and parkinsonism) and diagnostic biomarkers (reduced 
basal ganglia dopamine transporter uptake on SPECT or PET, polysomnographic confirmation of REM 
sleep behaviour without atonia and reduced cardiac MIBG uptake). The MCI-LB diagnostic criteria 
also highlight the importance of psychiatric symptoms in prodromal DLB, including the possibility of 
a ‘psychiatric-onset’ presentation. Five psychiatric symptoms – non-visual hallucinations, 
systematised delusions, apathy, anxiety and depression are listed as supportive features in both the 
DLB and MCI-LB criteria (McKeith et al., 2017). We have previously reported that the number of 
these symptoms present (the Neuropsychiatric Supportive Symptom Count) is greater in MCI-LB 
than in MCI due to Alzheimer’s disease (MCI-AD) (Donaghy et al., 2018) and that the presence of two 
or more of these symptoms is significantly more likely in MCI-LB than MCI-AD (likelihood ratio 4.2). 
In addition to different patterns of neuropsychiatric symptoms, MCI-LB and MCI-AD also 
demonstrate different cognitive profiles. MCI-LB is more likely to be associated with multiple domain 
amnestic or non-amnestic cognitive impairment, whereas single domain amnestic cognitive 
impairment is most likely to be the result of MCI-AD (Ferman et al., 2013). MCI-LB is associated with 
7 
 
particular deficits in verbal fluency, attention, executive and visuospatial function, with relative 
preservation of memory (Donaghy et al., 2018, Ciafone, Little, Thomas and Gallagher, 2019). 
The aim of this study was to replicate the findings from our initial MCI-LB cohort, demonstrating the 
effectiveness of the Lewy body Neuropsychiatric Supportive Symptom Count (NSSC) to differentiate 
between MCI-LB and MCI-AD (Donaghy et al., 2018). 
 
Hypotheses 
1. The presence of two or more neuropsychiatric supportive symptoms will be more common 
in MCI-LB than MCI-AD 
2. MCI-LB would be associated with greater visuospatial and executive dysfunction and less 
memory impairment than MCI-AD but these differences will not be sufficient to allow 




MCI subjects ≥60 years old were recruited from memory clinics, older people’s medicine clinics and 
neurology clinics in the North East of England and Cumbria. Potential participants were approached 
if they experienced symptoms which may be related to prodromal DLB, such as autonomic 
symptoms, visual disturbances, olfactory impairment and mood changes as well as any indication of 
the presence of core and supportive features of DLB. Subjects were excluded if they had a diagnosis 
of dementia, an MMSE score <20, a CDR score of >0.5, parkinsonism that developed more than one 
year prior to cognitive impairment or evidence of clinical stroke or a serious neurological or medical 
condition that would affect their performance in study assessments. Participants with symptomatic 
heart failure (New York Heart Association Class II or greater) were excluded to avoid false positive 
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cardiac MIBG results. Participants with a current episode of major depression or a history of bipolar 
disorder or schizophrenia were also excluded. 
All subjects gave their written informed consent to take part in the study. The study received ethical 
approval from the National Research Ethics Service Committee North East - Newcastle & North 
Tyneside 2 (Research Ethics Committee Identification Number 15/NE/0420). 
 
Neuropsychological Assessment 
Subjects had a thorough neuropsychological assessment including the Addenbrooke’s Cognitive 
Examination Revised (ACE-R) (Mioshi et al., 2006), FAS Verbal Fluency (Borkowski, Benton and 
Spreen, 1966), the Trail-making Test Parts A and B (Reitan, 1955), the Graded Naming Test (GNT) 
(McKenna and Warrington, 2007) and the Rey Auditory Verbal Learning Test (AVLT) (Rey, 1964), 




All patients were assessed by a doctor, who carried out a physical and neurological examination. 
Where one was available, an informant was also interviewed. Quantitative scales were used to 
assess neuropsychiatric symptoms (Geriatric Depression Scale (D'Ath, et al. 1994), Clinician 
Assessment of Fluctuations (Walker, et al. 2000), Dementia Cognitive Fluctuations Scale (DCFS) (Lee, 
et al. 2014), Neuropsychiatric Inventory (NPI) (Cummings, et al. 1994)), parkinsonism (Revised 
Unified Parkinson’s disease Rating Scale Motor Sub-scale (Goetz, et al. 2008)) and level of functional 
impairment (Instrumental Activities of Daily Living Scale (Lawton and Brody 1969), and Clinical 
Dementia Rating Scale (Hughes et al., 1982)). Neuropsychological assessment was carried out by 
trained nurses and Psychology graduates with experience in administering neuropsychological 
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assessments in research settings. Further clinical and neuropsychological assessments have been 
carried out annually. Baseline data will be reported in this manuscript. 
 
Neuropsychiatric Supportive Symptom Count 
The presence or absence of neuropsychiatric symptoms listed as ‘supportive clinical features’ in the 
DLB and MCI-LB diagnostic criteria (McKeith et al., 2017, McKeith et al., 2020) was determined from 
the relevant section of the Neuropsychiatric Inventory: delusions (Section A); non-visual 
hallucinations (Section B1/B4/B5/B6); depression (Section D), anxiety (Section E) and apathy (Section 
G). An affirmative response in the relevant section (severity and frequency scores ≥1) indicated the 
presence of the symptom. The Lewy Body Neuropsychiatric Supportive Symptom Count (NSSC) was 
defined as the total number of symptoms experienced by each patient (maximum=5). 
 
FP-CIT SPECT 
FP-CIT SPECT imaging was carried out at baseline. Three to six hours following a bolus intravenous 
injection of 185 MBq of 123I-FP-CIT (DaTSCAN, GE Healthcare, UK) patients were scanned using a 
double headed gamma camera (Siemens Symbia S) fitted with a low energy high resolution (LEHR) 
parallel hole collimator. Images were classed as normal or abnormal based on consensus visual 
rating by a five-person panel, blind to any clinical data (Benamer et al., 2000). 
 
MIBG 
Cardiac MIBG was carried out at baseline. A planar anterior image was acquired four hours after 
injection of 111 MBq of 123I-MIBG. The heart:mediastinum ratio (HMR) was calculated for each 
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participant, blind to clinical data. A HMR<1.86 considered abnormal based on local control data 
(Roberts et al., 2019). 
 
Diagnosis 
An expert consensus clinical panel (AJT, PCD, JPT) reviewed all the clinical assessment data to 
confirm subjects met NIA-AA all-cause MCI criteria (Albert et al., 2011) without considering 
aetiology. Where the first two raters did not agree, the third made a final decision. The consensus 
panel also rated the presence or absence of each of the four core symptoms of DLB (cognitive 
fluctuations, complex visual hallucinations, clinical parkinsonism and clinical RBD). This was all 
performed blind to FP-CIT SPECT and MIBG results. These symptom ratings and the imaging 
biomarker results were used to classify participants as probable MCI-LB (McKeith et al., 2020) (two 
core clinical features or one core clinical feature and at least one abnormal MCI-LB biomarker), 
possible MCI-LB (one core clinical feature or one abnormal MCI-LB biomarker) or MCI-AD (none of 
the four core features and no abnormal MCI-LB biomarkers with and evidence of decline consistent 
with AD with no evidence for another aetiology). Neuropsychiatric supportive symptoms were not 
used to classify participants as MCI-LB or MCI-AD.  The ‘one-year rule’ was applied so that no 
subjects had had evidence of Parkinsonism for more than a year before the onset of their cognitive 
decline. CSF and imaging biomarkers were not used in the diagnosis of MCI-AD, therefore the MCI-
AD cases fulfilled the NIA-AA ‘Core Clinical Criteria’ for MCI-AD. Assignment to these diagnostic 






Missing data (e.g. where an informant was not available or participants did not wish to complete the 
task) were excluded from the analyses as reported in the tables. Fourteen participants did not have 
data for the angle task as this was added to the test battery after the study commenced. 
Demographic and clinical data were compared using t-tests, Mann-Whitney U tests, Chi-squared and 
Fisher’s Exact tests depending on the nature of the data. Most data were non-parametric and 
resistant to normalisation. The effect of potential confounding factors on significant results in the 
cognitive data was tested using the general linear model with sex and prescription of cholinesterase 
inhibitors or memantine as covariates. This required the removal of outlying or influential values 
(standardised or studentised residual >±3, leverage>0.5, Cook’s Distance>1). Collinearity was 
excluded by ensuring correlation between independent variables was less than 0.7 and tolerance 
was greater than 0.1. Normality of residuals was assessed by visual inspection of P-P plots of 
standardised residuals. Scatter plots of studentised residuals against predicted values and partial 
regression plots were inspected to ensure the presence of linear relationships between the 
dependent and independent variables and homoscedasticity in the overall model. 
A post-hoc discriminant analysis was carried out to assess the ability of cognitive test results to 
differentiate between MCI-LB and MCI-AD. Tests which demonstrated a significant difference 
between MCI-LB and MCI-AD were included using the ‘enter’ method. Sensitivity and specificity 
were calculated with each case classified by functions derived from all other cases. 
 
Results 
Seventy-five participants completed baseline assessment, of which 30 were diagnosed with MCI-AD 
and 28 were diagnosed with probable MCI-LB (Figure 1). 17 were diagnosed with possible MCI-LB 
and were excluded from further analysis. 6 MCI-AD (20%) and 11 MCI-LB (39%) had at least one 
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follow-up assessment. In the probable MCI-LB group, RBD was the most common symptom (75%), 
followed by cognitive fluctuations (46%), parkinsonism (36%) and visual hallucinations (25%). 
 
INSERT FIGURE 1 HERE 
 
MCI-LB and MCI-AD groups were well balanced for age, predicted IQ and severity of cognitive 
impairment measured by the CDR (Table 1). The MCI-LB group was more likely to be male, to have 
an informant present and to be prescribed a cholinesterase inhibitor or memantine.  As expected, 
the MCI-LB group scored higher in the UPDRS, ESS and CAF, and were more likely to have RBD 
symptoms based on the Mayo sleep questionnaire. They also had greater NPI and NPI distress total 
scores and greater functional impairment measured by the IADL.  
 
INSERT TABLE 1 HERE 
 
The NPI defined symptoms of hallucinations, agitation/aggression and apathy were more frequently 
present, more severe and caused more caregiver distress in the MCI-LB group compared with the 
MCI-AD group (Table 2). Depression, anxiety, irritability/lability and appetite/eating disorder 
symptoms were also common in MCI-LB (>40% of participants), but were not significantly more 
common in MCI-LB than MCI-AD. 
 




The MCI-LB group reported more neuropsychiatric supportive symptoms (median MCI-LB 2 v 1 MCI-
AD, p<0.01; Table 3). 59% of MCI-LB had two or more symptoms compared with 9% of MCI-AD 
(likelihood ratio 6.5, p<0.001). 30% had three or more symptoms compared with 5% of MCI-AD 
(likelihood ratio=6.5, p=0.03; Table 3). 
 
INSERT TABLE 3 HERE 
 
MCI-LB participants recalled a greater proportion of items learned at Rey trial 5 on delayed recall, 
had a lower Trails ratio (A/B) and made more errors in the choice reaction task compared with MCI-
AD (Table 4). The effect of potential confounding variables on these results was tested using the 
general linear model with sex and prescription of cholinesterase inhibitor/memantine as covariates. 
One outlying result was excluded from the trails ratio analysis and two outlying results were 
excluded from the % Rey trial 5 delayed recall and CRT error analyses (studentised residuals >3). The 
results remained significant in % Rey trial 5 delayed recall (Beta=0.42, p=0.01) and Trails ratio (Beta=-
0.46, p=0.02). The difference in CRT error was no longer significant (Beta=0.27, p=0.16). 
 
INSERT TABLE 4 HERE 
 
A post-hoc discriminant analysis was carried out by entering the three cognitive tests that were 
significantly different between MCI-LB and MCI-AD (% Rey trial 5 recalled, Trails ratio, CRT error). 
This yielded a sensitivity of 63% and a specificity of 61% for the identification of MCI-LB, with an 





We found that neuropsychiatric symptoms were more common, more severe and caused more 
distress in MCI-LB compared with MCI-AD. We also found that MCI-LB was associated with greater 
impairment in executive function and less memory impairment than MCI-AD. MCI-LB cases were 
more likely to report two or more Lewy body neuropsychiatric supportive symptoms than MCI-AD, 
with a likelihood ratio of 6.5. 
 
This manuscript complements our previous report by repeating a detailed neuropsychiatric and 
cognitive profile of MCI-LB compared with MCI-AD. It is increasingly expected that treatment will 
only be effective when given in early disease stages in neurodegenerative disorders. In this context, 
the accurate identification of neurodegenerative dementias in their prodromal stage is vital to allow 
research into early disease stages and to identify participants for disease-modifying treatment trials. 
Our findings should help inform clinical and research practice in this emerging field. 
 
The importance of neuropsychiatric symptoms for future research studies 
Criteria for the diagnosis of MCI-LB have recently been developed (McKeith et al., 2020). The 
sensitivity and specificity for these criteria to identify MCI-LB are yet to be established, but the 
sensitivity may be lower than criteria for the dementia stage of DLB, as neuronal damage sufficient 
to cause core clinical features or abnormal biomarker findings will be less likely to have occurred at 
this earlier stage of the disease. The MCI-LB criteria recognise that other presentations of prodromal 
DLB are likely to exist, such as ‘psychiatric-onset’ and ‘delirium-onset’. We have now demonstrated 
in two independent cohorts that the presence of two or more neuropsychiatric supportive 
symptoms as defined by the MCI-LB diagnostic criteria is much more likely in MCI-LB than MCI-AD. 
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The presence of two or more symptoms in this cohort had a sensitivity of 59% and specificity of 91% 
for MCI-LB.  
The identification of MCI-LB cases to participate in research studies is difficult, as the diagnosis is 
currently not often made in clinical practice. Observational studies seeking to recruit MCI 
participants at risk of developing DLB could consider using the presence of two or more 
neuropsychiatric supportive symptoms as an inclusion criteria. Enquiring about these five symptoms 
with an informant is simple, does not necessarily require face-to-face contact and can be carried out 
by non-medical staff.  Such observational studies could determine whether the presence of 
neuropsychiatric supportive symptoms is predictive of later development of DLB in cases of MCI 
which have not yet developed any core diagnostic features of MCI-LB. 
 
The importance of neuropsychiatric symptoms in clinical practice 
There is increasing recognition of the importance of behavioural symptoms in the dementia 
prodrome. This has led to the development of the concept of mild behavioural impairment (which 
can exist alongside MCI) as a risk state for dementia (Ismail et al., 2016). The sensitivity and 
specificity of two or more supportive psychiatric features for the diagnosis of MCI-LB should prompt 
clinicians to enquire about these symptoms in clinical practice. The presence of such symptoms 
should raise suspicion of the presence of Lewy body disease and lead to further questioning and 
potentially investigations.  
In addition to the importance of these symptoms in diagnosis, our findings highlight the distress 
related neuropsychiatric symptoms experienced by people with MCI-LB and their family members 
(the NPI was completed by a spouse (n=25) or other family member (n=2) in all cases of MCI-LB). 
Participants with MCI-LB had higher total scores and total distress scores in the NPI. This is in 
keeping with our previous report (Donaghy et al., 2018) and with research in DLB, where higher NPI 
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scores and greater carer stress have been reported (Svendsboe et al., 2016). Apathy has been 
identified as significantly more common and severe in MCI-LB in both of our cohorts and is a source 
of significant stress for the family members of people with MCI-LB. Agitation/aggression was also 
significantly more common in this cohort and approached statistical significance in our original paper 
(p=0.06). Anxiety approached statistical significance in this paper (p=0.05) and was significant in our 
previous report. Depression, irritability and appetite/eating changes were also common, though 
these symptoms are less specific to MCI-LB. These results highlight the importance of enquiring 
about a range of neuropsychiatric symptoms in people with MCI, both to guide differential diagnosis, 
and to identify symptoms which cause distress for the person with MCI and the people around them. 
Some of these symptoms, such as depression or anxiety, may respond to psychological or 
pharmacological interventions, though the evidence base in MCI-LB is absent and the evidence from 
other Lewy body diseases including DLB and PD is inconclusive (Seppi et al., 2019, Taylor et al., 
2020). Even in the absence of evidence-based treatments, identifying of distressing symptoms and 
explaining their association with MCI-LB may be a source of comfort to people with MCI and their 
families and could help to guide care provision e.g. planned activities for people with apathy. The 
need for carer support in dementia is now well recognised and interventions for carers and family 
members have been developed (Livingston et al., 2019). Our study demonstrates that significant 
stress related to neuropsychiatric symptoms is present in the family members of people with MCI-LB 
and consideration needs to be given to needs of this group, despite the preservation of independent 
function in the person with MCI. 
It is notable that there was no difference between MCI-LB and MCI-AD in the Sleep domain of the 
NPI, despite RBD being the most common core diagnostic feature in the MCI-LB group. This 
highlights the insensitivity of the NPI for RBD and the need for specific assessment for RBD in 




The cognitive profile of MCI-LB 
The MCI-LB group demonstrated greater impairment in executive function with a lower trails A:B 
ratio and better memory measured by % Rey Trial 5 recalled following a delay. This is in keeping with 
the expected cognitive profile of MCI-LB, with greater executive function and less memory 
impairment.  However, the results are different to our previous cohort, which demonstrated worse 
verbal fluency and visuospatial function measured by the ACE and angle task. Previous research 
studies comparing MCI-LB with MCI-AD have demonstrated cognitive profiles in keeping with that 
observed in DLB - greater deficits attention, executive and visuospatial function with relatively 
preserved memory (Cagnin et al., 2015, Yoon et al., 2015, Sadiq et al., 2017, Ciafone et al., 2019). In 
keeping with our findings, the exact differences observed have differed between cohorts (e.g. 
backward digit span differences observed in Cagnin et al (2015) but not Yoon et al. (2015)). These 
inconsistencies may relate to relatively small samples sizes, but are also likely affected by significant 
heterogeneity of cognitive impairment in MCI-LB. As with our previous cohort, differences in 
cognitive tests could not accurately discriminate between MCI-LB and MCI-AD cases. From the 
research evidence available to date we can conclude that certain cognitive domains are likely to be 
particularly affected in MCI-LB such as executive and visuospatial function, whereas memory may be 
less affected. However, there is significant variability between individuals and the pattern of 
cognitive impairment based on simple analysis is not discriminatory. That said, more sophisticated 
analyses of cognitive data, for example using ex-Gaussian modelling to analyse attention dysfunction 
may shed more light on the differences between MCI-LB and MCI-AD (Schumacher et al., 2019). 
 
Strengths and Limitations 
We present a large cohort of probable MCI-LB and MCI-AD relative to the published literature. The 
cohort is well characterised with detailed clinical and cognitive assessment and imaging biomarkers. 
All but two participants had both cardiac MIBG and FP-CIT SPECT. That said, pathological diagnosis 
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remains the gold standard in dementia studies. Several participants in this cohort have consented to 
brain donation and data based on pathological diagnosis will emerge in the coming years. We 
excluded cases of possible MCI-LB due to uncertainty regarding their diagnosis, in keeping with our 
previous report (Donaghy et al., 2018). Data from the possible MCI-LB group is available in 
Supplementary Tables 1-4. Due to the relatively small size of this group, statistical comparisons were 
not performed. Findings in the NSSC remained similar when used in a mixed possible and probable 
MCI-LB group compared with MCI-AD (NSSC ≥2: Likelihood Ratio=5.8, p=0.01; NSSC≥3: Likelihood 
Ratio=6.3, p=0.03); Supplementary Table 3b).   
The study cohort was selected on the basis of possible symptoms of MCI-LB. This was necessary to 
ensure a high proportion of MCI-LB in the study sample. Possible symptoms related to MCI-LB were 
identified by research staff embedded in clinical settings, who were able to examine potential 
participants’ clinical notes. These symptoms included core diagnostic features as well as less specific 
symptoms such as olfactory disturbance, postural hypotension and recurrent falls. Local research 
staff have developed expertise in identifying these participants during our previous research study. 
Potential participants’ clinical notes included imaging results, which allowed the exclusion of 
participants with suspected vascular MCI. The pre-selected nature of our cohort should be borne in 
mind when applying the results to a clinical setting. 
The presence of current major depression was an exclusion criterion for the study. Most participants 
were recruited from psychiatry settings, where the presence of depression is thoroughly 
investigated during routine clinical assessment. Those with current active depression were not 
approached for participation. Participants with MCI and symptoms of psychosis (e.g. delusions or 
hallucinations) were included, as psychotic symptoms are known to be associated with DLB. Late-
onset psychosis could present with similar features. Long-term follow-up will determine the final 
clinical diagnosis for these participants. Follow-up data from our original cohort found a conversion 
rate to dementia of over 20% per year, in keeping with a well-characterised MCI cohort. 
19 
 
Antidepressant prescribing was higher in the MCI-LB group than the MCI-AD group. This is in keeping 
with our finding of greater neuropsychiatric symptoms in this group. Higher rates of treatment in the 
MCI-LB group may have reduced differences between MCI-LB and MCI-AD in the reported rates of 
depression and anxiety. 
Many participants, particularly those with MCI-LB, were receiving cholinesterase inhibitors or 
memantine. We believe this reflects a willingness of clinicians to use these medications in the MCI 
phase, particularly where they are confident that a neurodegenerative process in present. There was 
a significant imbalance in sex between MCI-LB and MCI-AD groups. DLB is more common in males 
than females (Kane et al., 2018), but the imbalance is above what would be expected. Positive 
findings in cognitive tests were repeated with sex and cholinesterase inhibitor/memantine 
treatment as covariates to ensure the results were not due to these potential confounders. 
The NPI is an informant rated scale, therefore the presence and absence of neuropsychiatric 
supportive features is based on informant report rather than expert clinical judgement. The criteria 
for MCI-LB state that ‘systematised delusions’ are a supportive feature. We cannot confirm from our 
data whether delusions were systematised or not. 
The MCI-LB group had greater functional impairment than the MCI-AD group and was more likely to 
be male. Lower scores in males have been noted in the Lawton IADL in Alzheimer’s disease 
(Bertrand, Willis and Sayer, 2001). As only one MCI-LB participant was female, we compared the 
male participants with MCI-LB and MCI-AD and found no significant difference in IADL score (median 
(IQR): MCI-LB 7 (5-8) v MCI-AD 7 (6.5-8); p=0.34). Greater functional impairment may be associated 
with greater ratings for apathy. However, diagnostic group was still significantly associated with the 
presence of apathy using logistic regression with IADL score as a covariate (Wald=11.7, p=0.001), 
whereas there was no significant association with IADL score (Wald=0.6, p=0.44). 
We did not use a threshold IADL score to determine the presence of significant functional 
impairment as a criterion for dementia. The IADL rates all-cause functional impairment, including 
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impairment related to physical health problems such as osteoarthritis. This is illustrated by a 
negative correlation between CIRS-G total score and IADL score within the cohort (Spearman’s ρ=-
0.35, p=0.01). To differentiate between MCI and dementia, the NIA-AA criterion of ‘preservation of 
independence of functional abilities’ was used (Albert et al., 2011). We agree with the authors of the 
NIA-AA criteria that the application of this description is challenging. In this study, the diagnosis of 
MCI was made by consensus panel based on a holistic assessment of each participant including 
consideration of comorbidities and previous levels of function. The cognitive data in this paper was 
analysed based on raw scores, reflecting current clinical practice and similar to the data that is likely 
to be available to screen participants for potential research studies. Multiple comparisons were 
made without statistical correction; however the key finding of significantly greater neuropsychiatric 
supportive symptoms in the MCI-LB group replicates our previous reported findings. 
 
Conclusions 
MCI-LB is associated with significantly more neuropsychiatric symptoms than MCI-AD and these 
symptoms are associated with significant stress for family members. The cognitive profile of MCI-LB 
differs from MCI-AD, with greater executive dysfunction and less memory impairment, but these 
differences are not sufficient to differentiate MCI-LB from MCI-AD. The presence of more than one 
neuropsychiatric supportive symptom as defined by MCI-LB criteria should alert clinicians to the 
potential presence of MCI-LB. The presence of these symptoms could also be used to identify 
participants at risk of MCI-LB in future observational research studies.  
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Table 1. Demographics and clinical scales  
MCI-AD MCI-LB p 
n 30 28  
Age, mean (SD) 75.2 (7.1) 74.6 (5.7) 0.73 
Sex, n (%) female 18 (60) 1 (4) <0.001 
NART IQ, median (IQR) 108 (105.5-117) 111 (103-115.8) 0.77 
CIRS-G Total, mean (SD) 6.2 (3.3) 8.2 (4.6) 0.07 
AChI/memantine prescribed, n (%) 8 (27) 18 (64) <0.01 
Antiparkinsonian prescribed, n (%) 0 (0) 2 (7) 0.23 
Antipsychotic prescribed, n (%) 0 (0) 0 (0) n/a 
Antidepressant prescribed, n (%) 5 (17) 12 (43) 0.03 
Anxiolytic prescribed, n (%) 0 (0) 2 (7) 0.23 
Informant present, n (%) 22 (73) 27 (96) 0.03 
UPDRS, median (IQR) 10.5 (3.8-24.0) 21 (12-35.8) 0.03 
NEVHI, median (IQR) 0 (0-1) 0 (0-4) 0.30 
ESS, median (IQR) 4 (2-9) 8 (6-12) 0.02 
DCFS, median (IQR) 7 (5.8-9) 8 (7-10) 0.13 
CAF, median (IQR) 0 (0-0) 3 (0-8) <0.01 
MSQ Q1, n (%) 0 (0) 22 (88) <0.001 
GDS, median (IQR) 3 (1-5.5) 3 (2-9.8) 0.41 
NPI Total, median (IQR) 6 (1-14.3) 15 (5-28) 0.02 
NPI Total Distress, median (IQR) 2 (0-7) 8 (2-16) <0.01 
IADL, median (IQR) 8 (7-8) 7 (5-8) 0.01 
CDR, median (IQR) 0.5 (0.5-0.5) 0.5 (0.5-0.5) 0.14 
Parametric data reported as mean (SD), non-parametric data reported as median 
(interquartile range).  
Mann-Whitney U tests, t, Chi-squared and Fisher’s Exact tests depending on the nature of 
the data.  
NART National Adult Reading Test; CIRS-G Cumulative Illness Rating Scale for Geriatrics; AChI 
Acetylcholinesterase inhibitor; UPDRS Unified Parkinson’s Disease Rating Scale (MDS 
Revision); NEVHI North East Visual Hallucinations Interview; ESS Epworth Sleepiness Scale; 
DCFS Diagnostic Cognitive Fluctuations Scale; CAF Clinician Assessment of Fluctuation; MSQ 
Mayo Sleep Questionnaire; GDS Geriatric Depression Scale; NPI Neuropsychiatric Inventory; 
IADL Instrumental Activities of Daily Living Scale; CDR Clinical Dementia Rating Scale.  
Informant based scales MCI-AD n=22, MCI-LB n=27. MSQ MCI-AD n=14, MCI-LB n=25. 




Table 2. Neuropsychiatric Inventory 
 Symptom Presence, n (%) Symptom Total 
(SeverityxFrequency), median 
(IQR) 
Distress Score, median (IQR) 
 
MCI-AD MCI-LB p MCI-AD MCI-LB p MCI-AD MCI-LB p 
Delusions 1 (5) 4 (15) 0.36 0 (0-0) 0 (0-0) 0.28 0 (0-0) 0 (0-0) 0.06 
Hallucinations 1 (5) 9 (33) 0.02 0 (0-0) 0 (0-1) 0.01 0 (0-0) 0 (0-0) 0.04 
Non visual Halls 0 (0) 4 (15) 0.12 - - - - - - 
Agitation/aggression 3 (14) 14 (52) 0.01 0 (0-0) 1 (0-2) 0.01 0 (0-0) 0 (0-2) 0.01 
Depression 7 (32) 11 (41) 0.52 0 (0-1) 0 (0-2) 0.31 0 (0-0) 0 (0-3) 0.07 
Anxiety 4 (18) 12 (44) 0.05 0 (0-0) 0 (0-3) 0.13 0 (0-0) 0 (0-2) 0.22 
Elation/euphoria 0 (0) 0 (0) 1.00 0 (0-0) 0 (0-0) 1 0 (0-0) 0 (0-0) 1 
Apathy/indifference 3 (14) 19 (70) <0.001 0 (0-0) 1 (0-8) <0.001 0 (0-0) 1 (0-3) <0.01 
Disinhibition 3 (14) 5 (19) 0.72 0 (0-0) 0 (0-0) 0.63 0 (0-0) 0 (0-0) 0.54 
Irritability/lability 4 (18) 11 (41) 0.09 0 (0-0) 0 (0-2) 0.07 0 (0-0) 0 (0-3) 0.08 
Aberrant motor behaviour 4 (18) 4 (15) 1.00 0 (0-0) 0 (0-0) 0.82 0 (0-0) 0 (0-0) 0.88 
Sleep 10 (48) 9 (35) 0.37 0 (0-4) 0 (0-2) 0.28 0 (0-0) 0 (0-1) 0.43 
Appetite/eating disorders 9 (41) 13 (48) 0.61 0 (0-1) 0 (0-4) 0.33 0 (0-0) 0 (0-2) 0.37 
Mann-Whitney, Chi-squared and Fisher’s Exact tests as appropriate. MCI-AD n=22, MCI-LB n=27 (except sleep – MCI-AD n=21, MCI-LB 
n=26). Bold denotes p<0.05. 
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Table 3. Neuropsychiatric Supportive Symptom Count  
MCI-AD MCI-LB LR p 
n 22 27 - - 
NSSC, median (IQR) 1 (0-1) 2 (1-3) - <0.01 
NSSC ≥2, n (%) 2 (9%) 16 (59%) 6.5 <0.001 
NSSC ≥3, n (%) 1 (5%) 8 (30%) 6.5 0.03 
Mann-Whitney, Chi-squared and Fisher’s Exact tests as appropriate. LR 
likelihood ratio; NSSC Neuropsychiatric Supportive Symptom Count. 




Table 4. Cognitive Tests 
 MCI-AD MCI-LB p 
n 30 28 - 
MMSE, mean (SD) 26.8 (2.1) 26.3 (2.4) 0.39 
ACE Total, mean (SD) 82.3 (8.1) 82.4 (9.6) 0.97 
ACE Att./Or., median (IQR) 17.5 (16-18) 18 (16-18) 0.87 
ACE Memory, mean (SD) 18.4 (5.0) 19.1 (4.7) 0.60 
ACE Fluency, median (IQR) 10 (7-11) 8 (7-10.8) 0.46 
ACE Language, median (IQR) 24 (22-25) 24.5 (22.3-25) 0.86 
ACE Visuospatial, median (IQR) 15 (14-16) 14 (13-16) 0.29 
% Rey Trial 5 Recalled, median (IQR) 14 (0-70) 52 (33-75) 0.03 
Rey Recognition, median (IQR) 12 (9-14) 12 (11-14) 0.37 
Trails A (s), median (IQR) 45 (35-67) 47 (39-67) 0.61 
Trails B (s), median (IQR) 90 (67-123) 112 (89-207) 0.05 
Trails Ratio (A/B) , median (IQR) 0.46 (0.38-0.54) 0.36 (0.26-0.47) 0.03 
Completed Trails A <300s, n (%) 29 (100) 27 (96) 0.49 
Completed Trails B <300s, n (%) 19 (66) 19 (68) 0.85 
FAS, mean (SD) 33.3 (10.8) 31.5 (12.0) 0.55 
GNT, median (IQR) 20 (16.5-23) 21 (19-24) 0.24 
SRT (s), median (IQR) 416 (331-433) 398 (341-470) 0.85 
SRT COV, median (IQR) 0.24 (0.16-0.33) 0.20 (0.18-0.29) 0.77 
CRT (s), median (IQR) 591 (537-734) 598 (537-759) 0.97 
CRT COV, median (IQR) 0.23 (0.20-0.30) 0.21 (0.18-0.28) 0.59 
CRT Error, median (IQR) 0.5 (0-2) 1.5 (0.8-3) 0.03 
CRT-SRT (s), median (IQR) 193 (167-290) 238 (156-297) 0.74 
Angle Task Result, median (IQR) 10.5 (7.4-13.0) 11.5 (7.9-22.3) 0.39 
Parametric data reported as mean (SD), non-parametric data reported as median (interquartile 
range).  
Mann-Whitney U tests, t, Chi-squared and Fisher’s Exact tests depending on the nature of the 
data. 
MMSE standardised Mini-Mental State Examination; ACE Addenbrooke’s Cognitive Examination; 
Rey AVLT Rey Auditory Verbal Learning Test; FAS FAS Verbal Fluency; GNT Graded Naming Test; 
SRT Simple Reaction Time; CRT Choice Reaction Time. 
Complete Rey AVLT data MCI-AD n=27, MCI-LB n=26; Trails A and B MCI-AD n=29, MCI-LB n=28; 
Trails Ratio MCI-AD n=20, MCI-LB n=23; GNT MCI-AD n=29, MCI-LB n=27; complete reaction time 
data MCI-AD n=27, MCI-LB n=26; Angle task MCI-AD n=23, MCI-LB n=21.  




Supplementary Table 1. Demographics and clinical scales  
MCI-AD Poss. MCI-LB Prob. MCI-LB 
n 30 17 28 
Age, mean (SD) 75.2 (7.1) 73.5 (8.4) 74.6 (5.7) 
Sex, n (%) female 18 (60) 9 (53) 1 (4) 
NART IQ, median (IQR) 108 (105.5-117) 100 (96.5-112.5) 111 (103-115.8) 
CIRS-G Total, mean (SD) 6.2 (3.3) 7.5 (2.7) 8.2 (4.6) 
AChI/memantine prescribed, n (%) 8 (27) 5 (29) 18 (64) 
Antiparkinsonian prescribed, n (%) 0 (0) 0 (0) 2 (7) 
Antipsychotic prescribed, n (%) 0 (0) 0 (0) 0 (0) 
Antidepressant prescribed, n (%) 5 (17) 5 (29) 12 (43) 
Anxiolytic prescribed, n (%) 0 (0) 0 (0) 2 (7) 
Informant present, n (%) 22 (73) 15 (88) 27 (96) 
UPDRS, median (IQR) 10.5 (3.8-24.0) 16 (8-23.5) 21 (12-35.8) 
NEVHI, median (IQR) 0 (0-1) 0.5 (0-5) 0 (0-4) 
ESS, median (IQR) 4 (2-9) 6 (3-10.5) 8 (6-12) 
DCFS, median (IQR) 7 (5.8-9) 8 (5-10) 8 (7-10) 
CAF, median (IQR) 0 (0-0) 0 (0-2) 3 (0-8) 
MSQ Q1, n (%) 0 (0) 0 (0) 22 (88) 
GDS, median (IQR) 3 (1-5.5) 3 (1-4.5) 3 (2-9.8) 
NPI Total, median (IQR) 6 (1-14.3) 3 (1-16) 15 (5-28) 
NPI Total Distress, median (IQR) 2 (0-7) 3 (0-14) 8 (2-16) 
IADL, median (IQR) 8 (7-8) 7 (5-8) 7 (5-8) 
CDR, median (IQR) 0.5 (0.5-0.5) 0.5 (0.5-0.5) 0.5 (0.5-0.5) 
Parametric data reported as mean (SD), non-parametric data reported as median 
(interquartile range).  
Poss. MCI-LB Possible MCI with Lewy bodies; Prob. MCI-LB Probable MCI with Lewy bodies 
NART National Adult Reading Test; CIRS-G Cumulative Illness Rating Scale for Geriatrics; AChI 
Acetylcholinesterase inhibitor; UPDRS Unified Parkinson’s Disease Rating Scale (MDS 
Revision); NEVHI North East Visual Hallucinations Interview; ESS Epworth Sleepiness Scale; 
DCFS Diagnostic Cognitive Fluctuations Scale; CAF Clinician Assessment of Fluctuation; MSQ 
Mayo Sleep Questionnaire; GDS Geriatric Depression Scale; NPI Neuropsychiatric Inventory; 
IADL Instrumental Activities of Daily Living Scale; CDR Clinical Dementia Rating Scale. 
Informant based scales MCI-AD n=22, poss. MCI-LB n=15, prob. MCI-LB n=27. MSQ MCI-AD 




Supplementary Table 2. Neuropsychiatric Inventory 
 Symptom Presence, n (%) Symptom Total 
(SeverityxFrequency), median 
(IQR) 

















Delusions 1 (5) 3 (20) 4 (15) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Hallucinations 1 (5) 6 (40) 9 (33) 0 (0-0) 0 (0-1) 0 (0-1) 0 (0-0) 0 (0-0) 0 (0-0) 
Non visual Halls 0 (0) 3 (20) 4 (15) - - - - - - 
Agitation/aggression 3 (14) 3 (20) 14 (52) 0 (0-0) 0 (0-0) 1 (0-2) 0 (0-0) 0 (0-0) 0 (0-2) 
Depression 7 (32) 5 (33) 11 (41) 0 (0-1) 0 (0-2) 0 (0-2) 0 (0-0) 0 (0-3) 0 (0-3) 
Anxiety 4 (18) 4 (27) 12 (44) 0 (0-0) 0 (0-1) 0 (0-3) 0 (0-0) 0 (0-0) 0 (0-2) 
Elation/euphoria 0 (0) 0 (0) 0 (0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Apathy/indifference 3 (14) 6 (40) 19 (70) 0 (0-0) 0 (0-4) 1 (0-8) 0 (0-0) 0 (0-2) 1 (0-3) 
Disinhibition 3 (14) 1 (7) 5 (19) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Irritability/lability 4 (18) 6 (40) 11 (41) 0 (0-0) 0 (0-2) 0 (0-2) 0 (0-0) 0 (0-2) 0 (0-3) 
Aberrant motor behaviour 4 (18) 2 (13) 4 (15) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Sleep 10 (48) 3 (27) 9 (35) 0 (0-4) 0 (0-2) 0 (0-2) 0 (0-0) 0 (0-0) 0 (0-1) 
Appetite/eating disorders 9 (41) 5 (33) 13 (48) 0 (0-1) 0 (0-1) 0 (0-4) 0 (0-0) 0 (0-0) 0 (0-2) 
Poss. MCI-LB Possible MCI with Lewy bodies; Prob. MCI-LB Probable MCI with Lewy bodies. MCI-AD n=22, Poss. MCI-LB n=15, Prob. MCI-




Supplementary Table 3a. Neuropsychiatric Supportive Symptom Count  
MCI-AD Poss MCI-LB Prob. MCI-LB 
n 22 15 27 
NSSC, median (IQR) 1 (0-1) 1 (0-3) 2 (1-3) 
NSSC ≥2, n (%) 2 (9%) 6 (40%) 16 (59%) 
NSSC ≥3, n (%) 1 (5%) 4 (27%) 8 (30%) 
Poss. MCI-LB Possible MCI with Lewy bodies; Prob. MCI-LB Probable MCI 
with Lewy bodies; NSSC Neuropsychiatric Supportive Symptom Count.  
 
 
Supplementary Table 3b. Neuropsychiatric Supportive Symptom Count  




n 22 42 - - 
NSSC, median (IQR) 1 (0-1) 2 (0-3) - 0.01 
NSSC ≥2, n (%) 2 (9%) 22 (52%) 5.8 0.01 
NSSC ≥3, n (%) 1 (5%) 12 (29%) 6.3 0.03 
Poss. MCI-LB Possible MCI with Lewy bodies; Prob. MCI-LB Probable MCI 
with Lewy bodies.  Mann-Whitney, Chi-squared and Fisher’s Exact tests 
as appropriate. LR likelihood ratio; NSSC Neuropsychiatric Supportive 




Supplementary Table 4. Cognitive Tests 
 MCI-AD Poss. MCI-LB Prob. MCI-LB 
n 30 17 28 
MMSE, mean (SD) 26.8 (2.1) 25.7 (3.0) 26.3 (2.4) 
ACE Total, mean (SD) 82.3 (8.1) 76.4 (11.5) 82.4 (9.6) 
ACE Att./Or., median (IQR) 17.5 (16-18) 17 (16-18) 18 (16-18) 
ACE Memory, mean (SD) 18.4 (5.0) 16.1 (5.0) 19.1 (4.7) 
ACE Fluency, median (IQR) 10 (7-11) 8 (4.5-10.5) 8 (7-10.8) 
ACE Language, median (IQR) 24 (22-25) 23 (20-24.5) 24.5 (22.3-25) 
ACE Visuospatial, median (IQR) 15 (14-16) 14 (12-16) 14 (13-16) 
% Rey Trial 5 Recalled, median 
(IQR) 14 (0-70) 38 (0-87) 52 (33-75) 
Rey Recognition, median (IQR) 12 (9-14) 11 (9-14) 12 (11-14) 
Trails A (s), median (IQR) 45 (35-67) 55 (36-83) 47 (39-67) 
Trails B (s), median (IQR) 90 (67-123) 95 (62-168) 112 (89-207) 
Trails Ratio (A/B) , median (IQR) 0.46 (0.38-0.54) 0.43 (0.32-0.56) 0.36 (0.26-0.47) 
Completed Trails A <300s, n (%) 29 (100) 15 (94) 27 (96) 
Completed Trails B <300s, n (%) 19 (66) 8 (50) 19 (68) 
FAS, mean (SD) 33.3 (10.8) 26.5 (11.4) 31.5 (12.0) 
GNT, median (IQR) 20 (16.5-23) 20 (15-23) 21 (19-24) 
SRT (s), median (IQR) 416 (331-433) 411 (330-759) 398 (341-470) 
SRT COV, median (IQR) 0.24 (0.16-0.33) 0.30 (0.23-0.54) 0.20 (0.18-0.29) 
CRT (s), median (IQR) 591 (537-734) 686 (548-929) 598 (537-759) 
CRT COV, median (IQR) 0.23 (0.20-0.30) 0.35 (0.20-0.45) 0.21 (0.18-0.28) 
CRT Error, median (IQR) 0.5 (0-2) 1 (0-2.5) 1.5 (0.8-3) 
CRT-SRT (s), median (IQR) 193 (167-290) 250 (193-346) 238 (156-297) 
Angle Task Result, median (IQR) 10.5 (7.4-13.0) 12.1 (7.3-19.6) 11.5 (7.9-22.3) 
Poss. MCI-LB Possible MCI with Lewy bodies; Prob. MCI-LB Probable MCI with Lewy bodies.  
Parametric data reported as mean (SD), non-parametric data reported as median (interquartile 
range).  
MMSE standardised Mini-Mental State Examination; ACE Addenbrooke’s Cognitive Examination; 
Rey AVLT Rey Auditory Verbal Learning Test; FAS FAS Verbal Fluency; GNT Graded Naming Test; 
SRT Simple Reaction Time; CRT Choice Reaction Time 
Complete Rey AVLT data MCI-AD n=27, poss. MCI-LB n=15, MCI-LB n=26; Trails A and B MCI-AD 
n=29, poss. MCI-LB n=16, prob. MCI-LB n=28; Trails Ratio MCI-AD n=20, poss. MCI-LB n=8, prob. 
MCI-LB n=23; GNT MCI-AD n=29, prob. MCI-LB n=27; complete reaction time data MCI-AD n=27, 
poss. MCI-LB n=14, prob. MCI-LB n=26; Angle task MCI-AD n=23, poss. MCI-LB n=10, prob. MCI-LB 
n=21. 
 
 
